Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- KOREAN JOURNAL OF INTERNAL MEDICINE32(4) · pp.656 · 2017
- 피인용
- Web of Science 7Scopus 11KCI 0
- FWCI (Scopus)
- 0.38
- JCR IF
- JCR 2016 1.729
- ISSN
- 1226-3303
저자
- Hong, Young Joon제1저자Department of Cardiology, Chonnam National University Hospital, Gwangju, South Korea
- Jeong, Myung Ho교신저자Department of Cardiology, Chonnam National University Hospital, Gwangju, South Korea
- Bae, Jang HoDepartment of Cardiology, Konyang University Hospital, Daejeon, South Korea
- Oh, Seok KyuDepartment of Cardiology, Wonkwang University Hospital, Iksan, South Korea
- Rha, Seung WoonDepartment of Cardiology, Korea University Guro Hospital, Seoul, South Korea
- Hur, Seung HoDepartment of Cardiology, Keimyung University Dongsan Medical Center, Daegu, South Korea
- Lee, Sung YunDepartment of Cardiology, Inje University Ilsan Paik Hospital, Goyang, South Korea
- Kim, Sang WookDepartment of Cardiology, Chung-Ang University Hospital, Seoul, South Korea
- 차광수Department of Cardiology, Pusan National University Hospital, Busan, South Korea
- Chae, In HoDepartment of Cardiology, Seoul National University Bundang Hospital, Seongnam, South Korea
- Ahn, Tae HoonDepartment of Cardiology, Gachon University Gil Medical Center, Incheon, South Korea
- Kim, Kee SikDepartment of Cardiology, Daegu Catholic University Medical Center, Daegu, South Korea
초록
Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy end-point was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (-42.05 +/- 32.73 mg/dL vs. -34.23 +/- 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (-20.16 +/- 54.49 mg/dL in 4 mg group and -24.45 +/- 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (-0.13% +/- 1.21% in 4 mg group and -0.04% +/- 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
키워드
Myocardial infarctionAtherosclerosisLipidsHydroxymethylglutaryl-CoA reductase inhibitorsC-REACTIVE PROTEINRANDOMIZED CONTROLLED-TRIALAVERAGE CHOLESTEROL LEVELSSTATIN THERAPYGLUCOSE-METABOLISMCORONARY ATHEROSCLEROSISPLAQUE VOLUMEATORVASTATINDISEASEHYPERCHOLESTEROLEMIA
식별자
- Scopus EID
- 2-s2.0-85025157051
- WoS UID
- 000405512900010
- KCI
- ART002240842



로그인
연구물 목록으로